Join Tom and Mike as they share an important update on Tom's prostate cancer journey. In this video, they discuss Tom's ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify ...

The second most common cancer among men is prostate cancer, affecting 1 in 8 men. Prostate cancer is treatable, in most cases, when the cancer remains localized to the prostate gland. But if the ...

One-third of patients with PSA levels below 0.2 ng/mL after radical prostatectomy have recurrent disease identifiable by PSMA PET. More than one-third of patients with PSA levels less than 0.5 ng/mL ...

A quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer as the current 30-40 minute scan and should be rolled out to make MRI scans more accessible to men who need one, ...

Millions of men could benefit from a new, faster prostate cancer scan. The quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer in clinical trials as the current 30- to ...

While prognoses for prostate cancer patients were once measured in months, experts say that advances in treatment and diagnosis now improve survival by years. By Gina Kolata Prostate cancer experts ...